GA-A mitigates the neurotoxin-induced apoptosis of dopaminergic neurons by inhibiting nuclear receptor co-activator 4 (NCOA4)-mediated ferritin autophagy, reducing the neurotoxicity, motor dysfunction, and loss of dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+), thereby alleviating the nervous system and providing a protective effect against Parkinson’s disease (PD) [102]. The gene discussed is NCOA4; the disease is Parkinson disease.